RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  2. Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05382728, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Locally advanced or metastatic NSCLC diagnosed by histology or cytology.

    Inclusion criterion 2

  3. Patients having recovered from all grade ≤ 1 toxicities related to previous anticancer therapies (CTCAE v 5.0) except for alopecia, platinum-therapy-related neuropathy (where ≤2 is allowed) before first dose of study treatment.

    Inclusion criterion 9

    Previous treatment with standard chemotherapy with 28 days before the first dose of the study drug, and traditional Chinese medicine antitumor therapy within 7 days before the first dose of the study drug;

    Exclusion criterion 4

    Patients currently receiving (or at least within 14 days prior to receiving the first dose )medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 isoenzyme (CYP)3A4;

    Exclusion criterion 8

    Participants in other clinical trials (other than non-interventional clinical trials) within 28 days prior to the first administration of the investigational drug.

    Exclusion criterion 10

  4. The ECOG score is 0-1, and there is no deterioration 2 weeks before the study, and the expected survival is not less than 3 months.

    Inclusion criterion 6

  5. Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites).

    Inclusion criterion 3

  6. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.

    Inclusion criterion 5

  7. Active human immunodeficiency virus (HIV), syphilis, hepatitis c virus (HCV) or hepatitis b virus (HBV) infection, with the exception of asymptomatic chronic hepatitis b or hepatitis c carriers.

    Exclusion criterion 20

  8. Pregnant or lactating women.

    Exclusion criterion 23

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05382728, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Male or female aged ≥18 years and <80 years.
  • Locally advanced or metastatic NSCLC diagnosed by histology or cytology.
  • Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites).
  • No prior systemic antitumor therapy for locally advanced or metastatic NSCLC.
  • At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
  • The ECOG score is 0-1, and there is no deterioration 2 weeks before the study, and the expected survival is not less than 3 months.
  • Adequate bone marrow reserve function, and no liver, kidney and coagulation dysfunction.
  • Male patients and female patients of reproductive age should take adequate contraceptive measures from signing informed consent to 3 months after the last study drug treatment; Women of childbearing age have negative pregnancy test results within 7 days of the first dose.
  • Patients having recovered from all grade ≤ 1 toxicities related to previous anticancer therapies (CTCAE v 5.0) except for alopecia, platinum-therapy-related neuropathy (where ≤2 is allowed) before first dose of study treatment.
  • Patients can understand and voluntarily sign the informed consent form.
  • Patient able to comply with study requirements.

Exclusion Criteria:

  • Any of the following treatment:
  • Previous treatment with EGFR inhibitor;
  • Previous treatment with Systematic antitumor therapy (including targeted therapy, biotherapy and immunodrug therapy, etc.);
  • Previous treatment with standard chemotherapy with 28 days before the first dose of the study drug, and traditional Chinese medicine antitumor therapy within 7 days before the first dose of the study drug;
  • Receiving radiation to more than 30% of the bone marrow or with a wide field of radiation that had to be completed within 28 days of the first dose of study treatment; Radiotherapy with a limited field of radiation within 7 days of the first dose of study treatment or palliative radiation therapy for bone metastasis;
  • Uncontrollable or poorly controlled pleural and abdominal effusion;
  • Major surgery within 28 days of the first dose of study treatment;
  • Patients currently receiving (or at least within 14 days prior to receiving the first dose )medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 isoenzyme (CYP)3A4;
  • Patients who are receiving and need to continue receiving medications during the study that are known to prolong the QTc interval or may cause tachycardia;
  • Participants in other clinical trials (other than non-interventional clinical trials) within 28 days prior to the first administration of the investigational drug.
  • Pathologically confirmed squamous cell carcinoma or squamous cell component predominance in NSCLC.
  • Symptomatic brain metastases or leptomeningeal metastases.
  • Patients have spinal cord compression caused by tumor.
  • Clinically severe gastrointestinal dysfunction may affect the ingestion, transport or absorption of the study drugs.
  • Cardiac function and disease are consistent with the following:
  • Corrected QT interval(QTc)≥ 470 milliseconds from 3 times of electrocardiograms (ECGs);
  • Any clinically important abnormalities in rhythm;
  • Any factors that increase the risk of QTc prolongation;
  • Left ventricular ejection fraction (LVEF) <50%.
  • Active human immunodeficiency virus (HIV), syphilis, hepatitis c virus (HCV) or hepatitis b virus (HBV) infection, with the exception of asymptomatic chronic hepatitis b or hepatitis c carriers.
  • Previous history of interstitial lung disease(ILD), drug-induced ILD or radiation pneumonitis require steroid treatment, or any evidence of clinically active ILD diseases.
  • Previous allogeneic bone marrow transplant.
  • Pregnant or lactating women.
  • Any other disease or medical condition that is unstable or may affect the safety or study compliance.
  • Hypersensitivity to investigational drug or similar compounds or excipients.

Quoted from ClinicalTrials.gov, NCT05382728, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05382728, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05382728